- For Quality Assurance: the development highlights the operational consequences of manufacturing disruption.
- For Regulatory Affairs: it requires close monitoring of EMA and national shortage information.
- For Manufacturing teams: it reinforces the importance of supply continuity when production depends on external manufacturing capacity.
EMA Flags Paliperidone Palmitate Shortage After Manufacturing Disruption
EMA said manufacturing problems at Pharmathen International caused the shortage of long-acting injectable paliperidone palmitate medicines.
The affected products are marketed by Advanz Pharma, Adamed Pharma, Alter, Belupo, Biogaran, EGIS Pharmaceuticals, Elpen, G.L. Pharma and Innovis Pharma. Moreover, EMA warned that availability of other long-acting injectable paliperidone palmitate medicines could also be affected in additional countries.
Paliperidone palmitate is used for maintenance treatment of schizophrenia in adults whose condition has already been stabilized with paliperidone or risperidone.
However, EMA made an important distinction. The supply disruption does not result from a known product quality defect or safety concern. Instead, the reported problem relates to manufacturing and medicine availability.
Why a Manufacturing Issue Is Now Affecting Medicine Supply Across Europe
This distinction matters for pharmaceutical quality leaders.
A medicine can face serious availability problems even when regulators have not identified a defect in the supplied product. Therefore, manufacturing continuity becomes an important operational consideration alongside traditional product-quality controls.
The current case also shows how a problem at one contract manufacturer can affect medicines sold by several marketing companies across multiple markets.
EMA has not announced when normal supply will resume. Consequently, healthcare professionals may need to consider alternative medicines where necessary. EMA’s shortage groups are monitoring the situation and engaging with the companies marketing the affected products.
If a critical medicine depended on one external manufacturing route, what evidence would give your Quality team confidence that supply could continue after a manufacturing disruption?
Consider manufacturing alternatives, escalation procedures, current supply visibility and documented contingency arrangements before choosing your answer.
What Pharma Quality and Manufacturing Teams Should Review Now
Teams responsible for affected or similarly outsourced products should take several immediate steps:
- Confirm exposure to the affected manufacturing route and current product availability.
- Review existing escalation and supply-continuity procedures for external manufacturers.
- Ensure Regulatory, Quality, Manufacturing and supply teams share the same current shortage information.
- Monitor EMA and relevant national shortage registers for changes in availability or mitigation measures.
These actions should remain proportionate to each company’s actual involvement and product exposure.
What Could Happen Next in the EU Paliperidone Palmitate Shortage
The key development will be any EMA update on the duration of the paliperidone palmitate shortage. Teams should also watch whether additional countries or products become affected and whether alternative supply reduces the shortage.
Any further statement from Pharmathen International or affected marketing companies could also clarify how the manufacturing problem and supply response develop.
How Zamann Pharma Supports Stronger Quality and Supply Risk Management
Zamann Pharma’s Quality Management System support helps pharmaceutical teams strengthen everyday quality processes, including deviations, CAPA, change control, risk management and audit readiness.
Source: Reuters.Com